Literature DB >> 7493346

Targeting of liver metastases of colorectal cancer with IgG, F(ab')2, and Fab' anti-carcinoembryonic antigen antibodies labeled with 99mTc: the role of metabolism and kinetics.

T Behr1, W Becker, E Hannappel, D M Goldenberg, F Wolf.   

Abstract

The aim of this study was to investigate targeting of the liver metastases by directly 99mTc-labeled complete (IgG) and fragmented antibodies [F(ab')2 and Fab'] in relation to their kinetics and metabolic fate. A total of 127 patients with metastatic colorectal cancer were examined [IgG1, BW 431/26 (Behringwerke, Marburg, Germany) n = 50; F(ab')2, F023C5 (Sorin Biomedica, Saluggia, Italy) n = 58; Fab', IMMU-4 (Immunomedics, Morris Plains, NJ) n = 19]. Native monoclonal antibodies (MAbs), serum samples from 10 min to 24 h postinjection (p.i.), and urine were analyzed by gel filtration chromatography. Kinetic data were deduced from whole-body and single-photon emission computed tomographic scans, performed 10 min to 24 h p.i. (region-of-interest technique). In BW 431/26, 96% of injected activity was labeled IgG1; in F023C5, 29% was F(ab')2, and 71% was Fab'; and in IMMU-4, 92% was Fab', and 8% was F(ab')2. Serum half-lives were: IgG1, 36 h (liver uptake predominant); F(ab')2, 16 h; and Fab', 4 h (renal uptake predominant). All MAbs were metabolized, fragments more rapidly than IgG, to low-molecular-weight products and excreted into the urine (e.g., Tc-cystine). In targeting liver metastases, sensitivities were found to be higher for fragments (44.1, 72.5, and 80% for BW 431/26, F023C5, and IMMU-4, respectively) but at significantly lower tumor:background ratios than with IgG (1.78 +/- 0.29 versus 1.29 +/- 0.11 and 1.43 +/- 0.53; P < 0.01). With IgG, there was a continuous tumor uptake over 24 h, whereas with fragments, the maximal uptake occurred mostly within 1 h, with subsequent clearance being slower for antigen-bound activity than for nonspecific background. Hence, diagnosis was possible mostly after 4 h with fragments but often not before 24 h with IgG. These results show that the higher sensitivity of fragments in liver lesion targeting at earlier p.i. times does not rely on an increased antibody uptake but on a more rapid clearance of nonspecific background activity due to faster metabolism and excretion. Intact MAbs show a slow, continuous uptake, leading to higher tumor:background ratios at later p.i. times, often beyond the imaging possibilities of 99mTc.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493346

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Resection of colorectal liver metastases revisited.

Authors:  J Scheele; C Rudroff; A Altendorf-Hofmann
Journal:  J Gastrointest Surg       Date:  1997 Sep-Oct       Impact factor: 3.452

2.  Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism.

Authors:  Yow-Ming C Wang; Bethlyn Sloey; Teresa Wong; Prerna Khandelwal; Rebeca Melara; Yu-Nien Sun
Journal:  Pharm Res       Date:  2011-04-08       Impact factor: 4.200

3.  High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment.

Authors:  A M Wu; P J Yazaki; S w Tsai; K Nguyen; A L Anderson; D W McCarthy; M J Welch; J E Shively; L E Williams; A A Raubitschek; J Y Wong; T Toyokuni; M E Phelps; S S Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

4.  Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab'.

Authors:  David J Macfarlane; Richard C Smart; Wendy W Tsui; Michael Gerometta; Paul R Eisenberg; Andrew M Scott
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-10       Impact factor: 9.236

5.  Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications.

Authors:  Tove Olafsen; Chia-Wei Cheung; Paul J Yazaki; Lin Li; Gobalakrishnan Sundaresan; Sanjiv S Gambhir; Mark A Sherman; Lawrence E Williams; John E Shively; Andrew A Raubitschek; Anna M Wu
Journal:  Protein Eng Des Sel       Date:  2004-01       Impact factor: 1.650

Review 6.  Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond.

Authors:  Javad Garousi; Anna Orlova; Fredrik Y Frejd; Vladimir Tolmachev
Journal:  EJNMMI Radiopharm Chem       Date:  2020-06-23

7.  A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis.

Authors:  Patrizia Murer; Louis Plüss; Dario Neri
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.